Navigation Links
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
Date:5/27/2009

Data show superiority of endoscopic ablation therapy using the HALO System for eradicating Barrett's esophagus in randomized, multicenter, sham controlled trial

SUNNYVALE, Calif., May 27 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical, Inc.) is highly effective for complete eradication of a pre-cancerous condition of the esophagus called Barrett's esophagus afflicting more than 3.3 million Americans. Additionally, ablative therapy using the HALO system reduced the risk of progression to cancer in the highest risk cohort studied (compared to control) from 19.0% to 2.4%.

The study entitled "Radiofrequency Ablation in Barrett's Esophagus with Dysplasia" is authored by lead investigator Nicholas J. Shaheen, M.D., Associate Professor of Medicine and Epidemiology, The University of North Carolina in Chapel Hill.

"This is a well-designed trial conducted in a rigorous manner at 19 expert U.S. centers, each having experience in the management of Barrett's esophagus, dysplasia, and cancer," said Dr. Shaheen. "Our results reported in the Journal are very promising, demonstrating superiority of ablation therapy for eliminating Barrett's and dysplasia, as well as reducing the rate of disease progression to more severe forms of dysplasia and esophageal cancer. This and data from other recent trials may ultimately change the paradigm for how gastroenterologists manage their patients with this disease."

As a result of chronic injury from gastroesophageal reflux disease (GERD), the normal esophageal lining is replaced with abnormal cells (Barrett's tissue), predisposing the patient to a higher risk for developing cancer of the esophagus. Patients with Barrett's who develop cancer, typically do so through a series of steps, starting with early Barrett's, then low
'/>"/>

SOURCE BARRX Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
2. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
5. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
6. Study Confirms Effectiveness of Innovative Prism Glasses For Hemianopia Patients
7. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
8. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
11. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... addition of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses ... in the United States . Reimbursement ... studied. Thorough product analyses for more than 73 SMBG ...
(Date:12/22/2014)... Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... treatment and management of epilepsy, today announced it will participate ... on Wednesday, January 14, 2015, in San Francisco ... and Chief Executive Officer, will speak at 11:00 AM Pacific ... accessed by clicking on the Investor Relations link on the ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Amgen (NASDAQ: AMGN ) today announced positive ... study of the pivotal Phase 3 fracture trial showing that ... osteoporosis was associated with continued increase in bone mineral density ... results will be presented on Nov. 8, 2011, at the ...
... Nov. 5, 2011 Supported by a patient-safety ... Radiologic Technology Week® kicks off Nov. 6. ... the theme for this year,s NRTW, Nov. 6-12. Selected by ... group of practicing R.T.s, it promotes a fundamental principle of ...
Cached Medicine Technology:Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial 9Passion for Patient Care Marks 2011 National Radiologic Technology Week® 2
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
(Date:12/25/2014)... Residents at Abernethy Laurels ... their generous spirit by providing holiday gifts to ... Network- Grandparents Raising Grandchildren program. , Following a ... largest Christmas tree on the campus of the ... of the Abernethy Village Association (AVA). Each holiday ...
(Date:12/24/2014)... 25, 2014 AlignLife of Wauwatosa ... afford certain items. During the holiday season, AlignLife looks forward ... 70 toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It ... joy, knowing that we are able to give kids toys ... not been for the generosity of our patients." , The ...
(Date:12/24/2014)... 24, 2014 Connie Casad, MD, a ... medicine advocate with 30 years of practice experience in ... the health benefits of dietary detoxification. The second study ... following excellent results from test patients who just completed ... explain her interest in conducting the study, Dr. Casad ...
(Date:12/24/2014)... New studies reveal that women under the age ... (March 6, 2014, JAMA Otolaryngology*). And although many people choose ... percent according to recent polls) facing hearing loss head on ... feels and relates to the world. People who have benefited ... by way of:, , self-confidence , ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6
... Now Have Access to Advanced Medical Expertise When Faced ... Nippon Life Benefits, a leading provider of employee ... members will have access to Best Doctors, an expert ... are getting the right diagnosis and treatment. The new ...
... COLUMBIA, S.C., Jan. 12 Medical travel company ... and individuals access lower-cost health care at accredited ... for providing useful information and outstanding customer service ... .The Columbia-based company received second-place honors in the ...
... cell findings could reveal targets for future treatments , , ... have discovered genes in prostate cancer cells that fuse ... occurrence that may initiate the development of some cancers. ... of Michigan Comprehensive Cancer Center, appear only in cancer ...
... 12 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... of medical devices worldwide, today announced selected preliminary,unaudited ... 2008. The,preliminary results reported below include the ... from Datascope ("DPM") starting from May,1, 2008. , ...
... 12 , - Small ... , With the introduction of ... messaging device, NEC sets new standards in,mobile communications and ... innovations. , (Photo: http://www.newscom.com/cgi-bin/prnh/20090112/333834 ...
... Reuters today announced that it has published a new ... expert insight from academics and key players in the ... the Drug Development Toolkit," it explores the role of ... challenges seen in clinical research and their potential ...
Cached Medicine News:Health News:Nippon Life Benefits Partners with Best Doctors to Help Members Make More Informed Health Care Decisions 2Health News:Nippon Life Benefits Partners with Best Doctors to Help Members Make More Informed Health Care Decisions 3Health News:Companion Global Healthcare Awarded for Outstanding Web Site 2Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:NEC's new M155 Messenger Sets New Standards in Mobile Messaging 2Health News:Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development 2Health News:Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development 3
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: